Point72 Hong Kong’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $273K | Buy |
+598
| New | +$244K | 0.01% | 296 |
|
|
2025
Q2 | – | Sell |
-3,795
| Closed | -$1.02M | – | 451 |
|
|
2025
Q1 | $1.02M | Buy |
+3,795
| New | +$975K | 0.07% | 207 |
|
|
2024
Q2 | – | Sell |
-15,971
| Closed | -$2.39M | – | 433 |
|
|
2024
Q1 | $2.39M | Buy |
+15,971
| New | +$2.66M | 0.12% | 186 |
|
|
2022
Q4 | – | Sell |
-44,547
| Closed | -$8.92M | – | 114 |
|
|
2022
Q3 | $8.92M | Buy |
+44,547
| New | +$8.5M | 0.31% | 68 |
|
|
2021
Q4 | – | Sell |
-3,900
| Closed | -$736K | – | 1853 |
|
|
2021
Q3 | $736K | Buy |
3,900
+3,470
| +807% | +$651K | 0.02% | 826 |
|
|
2021
Q2 | $73K | Buy |
+430
| New | +$63K | ﹤0.01% | 1389 |
|
|
2021
Q1 | – | Sell |
-453
| Closed | -$59K | – | 1770 |
|
|
2020
Q4 | $59K | Sell |
453
-129
| -22% | -$17.2K | ﹤0.01% | 1181 |
|
|
2020
Q3 | $85K | Sell |
582
-20,074
| -97% | -$2.85M | 0.01% | 589 |
|
|
2020
Q2 | $3.06M | Buy |
+20,656
| New | +$2.78M | 0.34% | 63 |
|
|
2020
Q1 | – | Sell |
-7
| Closed | -$1K | – | 926 |
|
|
2019
Q4 | $1K | Sell |
7
-2,718
| -100% | -$271K | ﹤0.01% | 1097 |
|
|
2019
Q3 | $219K | Sell |
2,725
-543
| -17% | -$43K | 0.06% | 276 |
|
|
2019
Q2 | $237K | Buy |
+3,268
| New | +$251K | 0.06% | 278 |
|
|
2018
Q4 | – | Sell |
-72
| Closed | -$6K | – | 867 |
|
|
2018
Q3 | $6K | Sell |
72
-290
| -80% | -$29.2K | ﹤0.01% | 691 |
|
|
2018
Q2 | $36K | Buy |
+362
| New | +$35.9K | 0.01% | 484 |
|
|
2018
Q1 | – | Sell |
-1,100
| Closed | -$140K | – | 875 |
|
|
2017
Q4 | $140K | Buy |
1,100
+560
| +104% | +$70.4K | 0.11% | 75 |
|
|
2017
Q3 | $63K | Sell |
540
-96
| -15% | -$8.19K | 0.04% | 210 |
|
|
2017
Q2 | $51K | Sell |
636
-223
| -26% | -$14.3K | 0.05% | 215 |
|
|
2017
Q1 | $44K | Buy |
859
+572
| +199% | +$26.4K | 0.06% | 260 |
|
|
2016
Q4 | $11K | Sell |
287
-447
| -61% | -$18.7K | 0.01% | 638 |
|
|
2016
Q3 | $50K | Sell |
734
-5,701
| -89% | -$402K | 0.03% | 470 |
|
|
2016
Q2 | $357K | Buy |
6,435
+400
| +7% | +$25.2K | 0.41% | 54 |
|
|
2016
Q1 | $379K | Buy |
+6,035
| New | +$401K | 0.74% | 41 |
|
|
2015
Q3 | – | Sell |
-706
| Closed | -$85K | – | 120 |
|
|
2015
Q2 | $85K | Buy |
706
+100
| +17% | +$11.9K | 0.17% | 101 |
|
|
2015
Q1 | $63K | Sell |
606
-113
| -16% | -$11.5K | 0.06% | 183 |
|
|
2014
Q4 | $70K | Buy |
+719
| New | +$66.6K | 0.07% | 361 |
|
Other funds holding ALNY
Point72 Hong Kong's ALNY Position: Q3 2025 in Review
Point72 Hong Kong opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2025: 598 shares worth $273K. The stake represents 0.01% of the portfolio and ranks #296 among its holdings. This is a return to the name: Point72 Hong Kong previously reported a position in ALNY as recently as Q1 2025.
Point72 Hong Kong first reported a position in ALNY in Q4 2014 and has held it in 25 quarters since. The position peaked at $8.92M in Q3 2022. 822 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.
- Point72 Hong Kong held 598 shares of Alnylam Pharmaceuticals worth $273K as of Q3 2025.
- Alnylam Pharmaceuticals was a new Point72 Hong Kong position in Q3 2025.
- Alnylam Pharmaceuticals made up 0.01% of Point72 Hong Kong's portfolio in Q3 2025, its #296 holding.
- Point72 Hong Kong first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 25 quarters since.
- Point72 Hong Kong's Alnylam Pharmaceuticals position peaked at $8.92M in Q3 2022.
- 822 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.
Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.